Green Thumb CEO Urges Federal Rescheduling

Context

Ben Kovler, founder and CEO of Green Thumb Industries, told Bloomberg on April 20, 2026 that federal rescheduling of cannabis could transform a roughly $30 billion U.S. industry overnight (Bloomberg, Apr 20, 2026). The core argument Kovler presented is that reclassification under federal drug law would remove a set of statutory and regulatory barriers — most notably restrictions on banking, research funding, and access to standard public capital markets — that have structurally suppressed the sector's growth and valuation. That $30 billion figure is widely cited in contemporary reporting as the approximate size of the U.S. legal cannabis market by retail sales; it serves as a baseline for assessing the scale of the regulatory drag and potential upside should federal posture change (Bloomberg, Apr 20, 2026). Kovler emphasized ancillary social-policy objectives — improved medical research and veteran access to care — while focusing primarily on the economic mechanics that tie the industry to constrained capital flows and higher financing costs.

The U.S. scheduling framework dates to the Controlled Substances Act of 1970, which placed cannabis in Schedule I, the category for substances considered to have no accepted medical use and a high potential for abuse (Controlled Substances Act, 1970). That classification underlies prosecutorial discretion, impedes federal grant-funded research, and leaves most commercial activity in a legal gray zone with banks and insurers. Congress has attempted piecemeal fixes — notably the SAFE Banking Act, which passed the House of Representatives in 2019 and again in 2021, but failed to become law in the Senate — confirming that legislative attempts to normalize banking relationships have repeatedly stalled (U.S. Congressional Record, 2019/2021). Kovler's Bloomberg appearance reframed the debate: rather than incremental accomodations, he argued that reclassification at the federal level would be a single policy action with cascading effects across financing, M&A, clinical trials, and state-level taxation regimes.

Kovler's commentary arrives in a market environment where public cannabis equities and specialized ETFs have underperformed broader benchmarks for years, reflecting both regulatory uncertainty and operational maturation challenges. Public peers have reported compressed margins relative to early investor expectations; capital intensity and lack of access to low-cost, conventional debt have forced many operators to dilute equity or seek high-yield private lenders. Those dynamics, Kovler argued, create a valuation wedge between U.S. operators and ancillary or international peers that benefit from clearer legal frameworks. The immediate policy ask is clear: federal rescheduling would not, on its own, guarantee profitable performance, but it would materially alter the cost of capital and competitive landscape that currently underpin investor expectations.

Data Deep Dive

Three data points anchor Kovler's thesis and warrant scrutiny. First, the $30 billion U.S. market figure cited in the Bloomberg interview provides a scale for retail demand and tax revenues in states where cannabis is legal (Bloomberg, Apr 20, 2026). Second, the legal classification of cannabis as Schedule I under the Controlled Substances Act of 1970 remains the statutory barrier to federal-level medical research and banking normalization (Controlled Substances Act, 1970). Third, the legislative record shows that the SAFE Banking Act passed the U.S. House in 2019 and 2021 but did not secure final enactment in the Senate, illustrating the limits of legislative avenues to date (U.S. Congressional Record, 2019/2021). Together these data points form the empirical backbone for claims that a single executive-branch rescheduling decision or comprehensive congressional action would have outsized effects.

Translating rescheduling into financial mechanics requires mapping changes to credit spreads, cost of capital, and M&A activity. Currently, many operators borrow from specialized lenders or rely on equity; anecdotal spreads on cannabis-specific loans have historically been multiple percentage points above comparable investment-grade corporate debt, reflecting legal and reputational risk. Rescheduling would not eliminate all credit risk but would likely compress spreads by reintroducing mainstream banks and federally insured deposit flows to the sector, which in turn could reduce weighted-average cost of capital by several hundred basis points for well-run operators. That hypothetical compression is comparable to past regulatory-driven decompressions in other sectors: for example, post-Glass-Steagall-era adjustments in the 1990s altered capital structures across the banking and securities industries, demonstrating how regulatory change can recalibrate financing norms over a multi-year transition.

On the research front, reclassification would permit FDA-regulated clinical trials and federally funded research programs to engage directly with commercial growers and product developers. Today, Schedule I status obstructs broad NIH-funded cannabis research and complicates randomized controlled trials that insurers and guideline committees favor. From a health-economics perspective, better evidence generation could shift prescribing patterns and payer attitudes — a feedback loop that could expand medical demand, alter product mixes, and increase per-customer lifetime value for medical-focused operators. These mechanisms are measurable: increases in clinical-grade trials and peer-reviewed publications typically precede mainstream payer acceptance in therapeutic categories, and rescheduling would likely accelerate that transition.

Sector Implications

If federal rescheduling were implemented, the most immediate beneficiaries would likely be vertically integrated MSOs (multi-state operators) and ancillary service providers that can scale quickly to absorb newly available capital. Access to conventional debt markets would favor companies with clean corporate governance, audited financials, and state-compliant operations. Over a three- to five-year horizon, one should expect increased consolidation as larger players deploy lower-cost capital to purchase smaller, undercapitalized operators, compressing the number of regional independents. This dynamic mirrors consolidation waves in other nascent regulated sectors once federal clarity emerges, such as the legal gambling and sports-betting industries post-regulatory liberalization.

Taxation and state-federal coordination would represent both opportunity and complexity. States that currently collect substantial excise taxes might see revenue streams expand with higher legal participation and the attraction of corporate investment, but they could also face transitional administrative challenges in reconciling federal tax treatment under IRC Section 280E, which currently bars deductions for businesses trafficking in Schedule I substances. Rescheduling would likely trigger legislative and administrative reviews of 280E's applicability, a change with direct implications for net margins. For institutional investors, the key vectors to monitor are prospective changes to federal tax treatment, bank participation rates, and a timetable for FDA-recognized clinical research programs.

International competitors and cross-border supply chains will also respond. Canadian and European cannabis firms that benefited from clearer national frameworks have at times commanded premium multiples relative to U.S. peers; a U.S. rescheduling could narrow that gap, altering cross-border M&A incentives. Conversely, rescheduling could invite more intense global competition, particularly in medicinal formulations, as U.S. scientific institutions increase output and product sophistication. Investors and corporate strategists should therefore consider not only domestic regulatory shifts but also how rescheduling reshapes comparative advantage at the firm and country level.

Risk Assessment

Timing risk is paramount: reclassification requires executive-branch or congressional action and would face legal and political challenges. Even an administrative rescheduling by the Drug Enforcement Administration involves notice-and-comment rulemaking and potential litigation, meaning a process measured in months to years rather than days. Market actors that price in immediate change risk a mismatch between public statements and policy reality. This timing uncertainty creates execution risk for companies that might pursue aggressive M&A or capex strategies premised on rapid normalization of capital access.

Policy design risk is equally significant. The form of rescheduling — whether to Schedule II, III, or different regulatory carve-outs — determines how quickly banks, insurers, and federal research entities can engage. Partial solutions, such as limited rescheduling for specific derivatives or medicinal cannabinoids, would create uneven effects across the value chain, benefiting some segments (pharmaceutical-grade R&D) while leaving retail operations in continued legal ambiguity. Investors should therefore triangulate plausible policy scenarios and stress-test models for differing implementation paths.

Market risk persists even under the most favorable policy outcome. Increased capital access could catalyze a surge of supply that depresses wholesale prices, especially in markets with limited retail outlets or slow consumer demand growth. Historical precedents in other commoditized consumer categories show that supply-led price compression can erode gross margins despite top-line growth. Corporate governance and execution quality will therefore determine which operators capture market share and preserve profitability amid industry expansion.

Fazen Markets Perspective

From the Fazen Markets vantage point, the binary framing — rescheduling equals immediate, unalloyed upside — is too simplistic. Our contrarian read is that rescheduling will shift the investment bar from regulatory arbitrage to operational excellence and capital allocation skill. In a reclassified environment, the market will rapidly differentiate firms with disciplined cost structures, scalable retail footprints, and product differentiation. Companies that earned high valuations in the private markets through growth at any cost could be exposed to rapid re-rating as cheap capital reveals their true unit economics. Investors should not assume that access to banks and debt automatically converts to profitable scale; rather, it will expose weaker operators to market-driven consolidation.

We also highlight a non-obvious implication: rescheduling could accelerate vertical de-integration among certain incumbents. If debt markets favor asset-light models and private equity seeks roll-up opportunities, large multi-state operators may spin off or sell underperforming retail assets to focus on branded products and supply chain control. That strategic pivot would create differentiated return profiles across equity, credit, and private capital strategies. For institutional portfolios anticipating regulatory normalization, the critical lens should be firm-level capital discipline and the ability to execute M&A without overpaying in a capital-rich environment. For further reading on regulatory-driven sector transformations, see our coverage at topic and our sector playbook on regulated consumer industries topic.

Outlook

Under an optimistic timeline — where rescheduling is initiated by the administration and survives legal scrutiny — measurable normalization of banking and research could begin within 6–18 months, with tangible capital-market effects visible within 12–36 months. That timeline would permit a wave of refinancing, selective M&A, and expansion of clinical trials. Under a slower or contested scenario, the industry may see only incremental relief via targeted legislation or administrative guidance, producing more modest improvements in financing conditions. Investors and policymakers should therefore track three leading indicators: changes in bank participation levels (number of banks serving state-legal operators), the volume of FDA-registered cannabis clinical trials, and legislative action on Section 280E tax treatment.

From a market-structure standpoint, expect volatility during the transition as capital re-rates firms, and as operational metrics — yields, retail same-store sales, and wholesale prices — adjust. Risk premia may compress unevenly, benefitting companies with low leverage and clear compliance records. For portfolio construction, this suggests a multi-stage approach that separates short-term event-driven trades from longer-term value plays grounded in durable franchise economics.

Bottom Line

Ben Kovler's Bloomberg comments on April 20, 2026 reframe a persistent policy debate by tying rescheduling directly to quantifiable shifts in capital access, research, and valuation across a $30 billion U.S. cannabis market (Bloomberg, Apr 20, 2026). The policy mechanics are clear; the investment outcomes will hinge on timing, implementation details, and firm-level execution.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

FAQ

Q: How would federal rescheduling change banking relationships for cannabis companies?

A: Rescheduling would materially reduce legal risk for federally regulated banks to engage with state-legal cannabis businesses, enabling access to insured deposit services and standard lending products. In practice, banks would need updated regulatory guidance and internal compliance frameworks; the pace of onboarding would depend on risk tolerance and supervisory expectations. This FAQ expands on issues around anti-money-laundering compliance and correspondent banking that were not covered in the main body.

Q: What is a realistic timeline from rescheduling to normalized capital markets?

A: If rescheduling occurs via administrative action and survives legal challenge, initial banking improvements could appear within 6–18 months, with broader capital-market normalization (refinancings, bond issuance) in a 12–36 month window. Litigation, contested rulemaking, or incremental legislative fixes would extend that timetable. Historical administrative rulemaking and court reviews in adjacent sectors support these multi-stage timelines.

Q: Are there historical parallels that inform how markets might react?

A: Yes. Regulatory liberalizations in sectors such as online gambling and sports betting — where state and federal interplay created phased market openings — show initial volatility followed by consolidation and valuation re-rating as capital flows and regulatory clarity mature. Those precedents suggest a multi-year pathway from policy change to stabilized valuations.